Published in Oncotarget on June 07, 2016
Contribution of Upregulated Dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC). Int J Cancer (2016) 0.77
The Prognostic and Clinicopathological Significance of Tumor-Associated Macrophages in Patients with Gastric Cancer: A Meta-Analysis. PLoS One (2017) 0.76
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PLoS One (2017) 0.75
Pathologic evaluation of tumor-associated macrophage density and vessel inflammation in invasive breast carcinomas. Oncol Lett (2017) 0.75
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials (2007) 14.51
Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69
Macrophage polarization in tumour progression. Semin Cancer Biol (2008) 4.62
M1 and M2 Macrophages: Oracles of Health and Disease. Crit Rev Immunol (2012) 2.49
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell (2014) 2.40
Expression of CD68 in non-myeloid cell types. Scand J Immunol (2008) 2.32
Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer (2008) 2.32
Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol (2004) 2.26
Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One (2012) 2.14
M1 and M2 macrophages: the chicken and the egg of immunity. J Innate Immun (2014) 2.06
The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer (2010) 2.03
Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 1.95
Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res (2003) 1.89
Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol (2005) 1.87
Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J (2009) 1.80
Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) (2014) 1.74
Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol (2013) 1.54
High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer (2008) 1.41
Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology (1999) 1.38
The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer (2010) 1.30
The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology (2009) 1.28
TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med (2007) 1.24
Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol (2013) 1.14
Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol (2010) 1.12
Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol (2012) 1.10
Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. Lung Cancer (2013) 1.04
M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) (2011) 1.03
Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of Cd204-positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol (2012) 0.97
Advances in adjuvant systemic therapy for non-small-cell lung cancer. World J Clin Oncol (2014) 0.90
Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages. Cancer Res (2012) 0.89
The role of tumor-associated macrophages in tumor vascularization. Vasc Cell (2013) 0.87
Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma. Lung Cancer (1999) 0.84
Immunologic checkpoint blockade in lung cancer. Semin Oncol (2015) 0.83
Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery. Am J Transl Res (2014) 0.83
Interstitial tumor-associated macrophages combined with tumor-derived colony-stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non-small cell lung cancer. J Thorac Cardiovasc Surg (2014) 0.83
Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment. Drug Des Devel Ther (2014) 0.81
Different morphology, stage and treatment affect immune cell infiltration and long-term outcome in patients with non-small-cell lung carcinoma. Histopathology (2012) 0.80